ARVINAS INC
NASDAQ: ARVN (Arvinas, Inc.)
Kemas kini terakhir: 7 jam lalu7.41
-0.02 (-0.27%)
| Penutupan Terdahulu | 7.43 |
| Jumlah Dagangan | 585,121 |
| Harga / Jualan (P/S) | 1.66 |
| Harga / Buku (P/B) | 0.910 |
| Julat 52 Minggu |
| Margin Keuntungan | -10.92% |
| Margin Operasi (TTM) | 37.82% |
| EPS Cair (TTM) | -0.660 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 646.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.59% |
| Nisbah Semasa (MRQ) | 4.58 |
| Aliran Tunai Operasi (OCF TTM) | -250.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.69 M |
| Pulangan Atas Aset (ROA TTM) | -5.39% |
| Pulangan Atas Ekuiti (ROE TTM) | -7.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Arvinas, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -1.50 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 6.89% |
| % Dimiliki oleh Institusi | 90.98% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Pfizer Inc | 30 Jun 2026 | 3,457,815 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |